EMEA-002632-PIP01-19

Key facts

Active substance
satoreotide trizoxetan
Therapeutic area
Diagnostic
Decision number
P/0390/2019
PIP number
EMEA-002632-PIP01-19
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
  • Diagnosis of breast cancer
  • Diagnosis of lung cancer
  • Diagnosis of neuroendocrine tumours (excluding neuroblastoma)
Route(s) of administration
Intravenous use
Contact for public enquiries
Ipsen Pharma

E-mail: caroline.pallardy@ipsen.com
Tel. +33 671197553

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating